Safety monitoring and information
Understand the ways we work to ensure medicines and medical devices remain as safe and effective as possible. Access information on product safety topics.
This page is in Beta testing. We welcome your feedback and suggestions as we look to improve this page.
What safety means
Safety is determined by weighing the known and potential risks, against the expected benefits when a therapeutic good is used as intended. While some risks are identified during the approval process, others may only become apparent after broader use.
The safety of therapeutic goods is a shared responsibility between regulators, sponsors, healthcare professionals and consumers.
How we monitor safety
We monitor safety through a range of different activities:
- Pre-market evaluation: Products must meet strict safety, quality and efficacy standards before being included in the Australian Register of Therapeutic Goods (ARTG).
- Post-market surveillance: We monitor products once they are on the market through adverse event reports, product testing, recalls and safety reviews.
- Adverse event reporting: Anyone can report adverse events or side effects, product defects or safety concerns. These reports help identify emerging risks and inform regulatory action.
- Product testing and investigations: Our laboratories test therapeutic goods to ensure they meet Australian standards and compare results with international benchmarks. See further information on our Product testing and investigations.
- Recalls and market actions: If a safety issue is identified, we may initiate recalls, issue safety alerts or require product corrections.
A key activity in safety monitoring is identifying patterns that emerge when problems are reported by sponsors, health professionals and consumers. An adverse event occurring does not necessarily mean that there is something wrong with a therapeutic good. However, each report helps to build a picture of the safety profile of a product. You can Report an adverse event or safety problem.
Latest alerts
-
We are warning consumers about the risks of importing and using unapproved peptide products that are promoted online.
-
We are advising consumers that Artri Ajo King tablets may pose a serious risk to your health and should not be taken.
-
GlaxoSmithKline (GSK) Australia Pty Ltd is issuing a product correction for certain batches of their Flixotide and Pavtide Accuhalers as a small number of Accuhalers may not automatically reload the next dose.
Latest articles
-
Product Information safety updates - April 2026
Information for health professionals about medicines with safety related updates to their Product Information. -
Enforceable direction: Veganic SKN Limited
The delegate believes, on reasonable grounds, that it is in the interests of public health or safety to give Veganic SKN Limited directions under section 42YT of the Therapeutic Goods Act 1989. -
Three Victorians arrested following seizure of over $2 million worth of steroids and peptides by the ABF and TGA
Two Victorian men and one woman have been charged following a joint investigation into an alleged criminal syndicate importing Performance and Image Enhancing Drugs (PIEDs) into Australia.
Latest publications
-
Advisory Committee on Vaccines meeting statement 56
-
Find out about the seasonal influenza vaccines available for the 2026 southern hemisphere season.
-
Advisory Committee on Vaccines meeting statement 55